PL437895A1 - Way to determine the risk of cancer in men according to the concentration of copper in the blood - Google Patents

Way to determine the risk of cancer in men according to the concentration of copper in the blood

Info

Publication number
PL437895A1
PL437895A1 PL437895A PL43789521A PL437895A1 PL 437895 A1 PL437895 A1 PL 437895A1 PL 437895 A PL437895 A PL 437895A PL 43789521 A PL43789521 A PL 43789521A PL 437895 A1 PL437895 A1 PL 437895A1
Authority
PL
Poland
Prior art keywords
blood
cancer
copper
concentration
risk
Prior art date
Application number
PL437895A
Other languages
Polish (pl)
Other versions
PL243834B1 (en
Inventor
Jan LUBIŃSKI
Cezary Cybulski
Jacek Gronwald
Tomasz Huzarski
Róża Derkacz
Wojciech MARCINIAK
Anna Jakubowska
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL437895A priority Critical patent/PL243834B1/en
Publication of PL437895A1 publication Critical patent/PL437895A1/en
Publication of PL243834B1 publication Critical patent/PL243834B1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określenia ryzyka zachorowania na raka u mężczyzn poniżej 50 roku życia, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia miedzi we krwi osoby badanej, przy czym stężenie wskazuje na tendencję do 3 krotnie zmniejszonego ryzyka zachorowania na raka w stosunku do podgrupy o wysokim stężeniu miedzi we krwi (814,39 µg/l), w przypadku występowania wartości stężenia miedzi we krwi < 814 µg/l.The subject of the application is a method for determining the risk of cancer in men under 50, characterized in that it includes a quantitative assessment of the concentration of copper in the blood of the test person, the concentration indicating a tendency to a 3-fold reduced risk of cancer in relation to the subgroup with high blood copper level (814.39 µg/l) if your blood copper level is < 814 µg/l.

PL437895A 2021-05-19 2021-05-19 Method of determining the risk of cancer in men depending on the concentration of copper in the blood PL243834B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL437895A PL243834B1 (en) 2021-05-19 2021-05-19 Method of determining the risk of cancer in men depending on the concentration of copper in the blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL437895A PL243834B1 (en) 2021-05-19 2021-05-19 Method of determining the risk of cancer in men depending on the concentration of copper in the blood

Publications (2)

Publication Number Publication Date
PL437895A1 true PL437895A1 (en) 2022-11-21
PL243834B1 PL243834B1 (en) 2023-10-16

Family

ID=84191870

Family Applications (1)

Application Number Title Priority Date Filing Date
PL437895A PL243834B1 (en) 2021-05-19 2021-05-19 Method of determining the risk of cancer in men depending on the concentration of copper in the blood

Country Status (1)

Country Link
PL (1) PL243834B1 (en)

Also Published As

Publication number Publication date
PL243834B1 (en) 2023-10-16

Similar Documents

Publication Publication Date Title
Pirola et al. Selenium supplementation in patients with subclinical hypothyroidism affected by autoimmune thyroiditis: Results of the SETI study
Hallett et al. Estimates of HIV incidence from household-based prevalence surveys
BR112022007386A2 (en) METHODS TO TREAT HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-IL)-4-((2-FLUORO-4-((3-MORPOLINOAZETIDIN-1-YL)METHYL)BENZYL )AMINO)ISOINDOLINE-1,3-DIONE
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
DE602005014386D1 (en) USE OF CYFRA 21-1 AND OSTEOPONTIN AS A MARKER FOR COLORECTAL CARCINOMAS
Del Romero et al. Absence of transmission from HIV-infected individuals with HAART to their heterosexual serodiscordant partners
PL437046A1 (en) Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland
PL437895A1 (en) Way to determine the risk of cancer in men according to the concentration of copper in the blood
BR112019025079A2 (en) ELECTROCHEMICAL BIOSENSORS
PL437898A1 (en) Way to determine the risk of cancer in men depending on the concentration of selenium in the blood
PL438655A1 (en) Method of determining the risk of cancer in women depending on concentration of lead in the blood
PL437896A1 (en) Way to determine the risk of cancer in men according to the concentration of arsenic in the blood
PL437897A1 (en) Way to determine the risk of cancer in men according to the concentration of cadmium in the blood
PL437894A1 (en) Way to determine the risk of cancer in men according to the concentration of zinc in the blood
PL431092A1 (en) Buffer solution and its application in electrochemical impedance spectroscopy
PL439315A1 (en) The method of determining the risk of cancer in women depending on the concentration of selenium in the blood
PL437899A1 (en) Way to determine the risk of cancer in men according to the concentration of lead in the blood
PL437608A1 (en) Method of determining the risk of cancer in women according to the concentration of cadmium in the blood
PL433150A1 (en) Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level
Sholtz et al. Assaying organochlorines in archived serum for a large, long-term cohort: implications of combining assay results from multiple laboratories over time
PL439313A1 (en) Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood
PL438563A1 (en) Serum selenium concentration as a marker of survival in patients with malignant melanoma in Poland
PL407244A1 (en) Electrochemical bio-sensor for detecting S100B protein
PL439316A1 (en) How to determine the risk of cancer in women according to the concentration of zinc in the blood
PL414266A1 (en) Concentration of selenium in blood as a risk factor for cancers in women